Cargando…
Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant
Co-ligation of the B cell antigen receptor with complement receptor 2 on B-cells via a C3d-opsonised antigen complex significantly lowers the threshold required for B cell activation. Consequently, fusions of antigens with C3d polymers have shown great potential in vaccine design. However, these lin...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336717/ https://www.ncbi.nlm.nih.gov/pubmed/30687332 http://dx.doi.org/10.3389/fimmu.2018.03139 |
_version_ | 1783388101118263296 |
---|---|
author | Yang, Yi Back, Catherine R. Gräwert, Melissa A. Wahid, Ayla A. Denton, Harriet Kildani, Rebecca Paulin, Joshua Wörner, Kristin Kaiser, Wolgang Svergun, Dmitri I. Sartbaeva, Asel Watts, Andrew G. Marchbank, Kevin J. van den Elsen, Jean M. H. |
author_facet | Yang, Yi Back, Catherine R. Gräwert, Melissa A. Wahid, Ayla A. Denton, Harriet Kildani, Rebecca Paulin, Joshua Wörner, Kristin Kaiser, Wolgang Svergun, Dmitri I. Sartbaeva, Asel Watts, Andrew G. Marchbank, Kevin J. van den Elsen, Jean M. H. |
author_sort | Yang, Yi |
collection | PubMed |
description | Co-ligation of the B cell antigen receptor with complement receptor 2 on B-cells via a C3d-opsonised antigen complex significantly lowers the threshold required for B cell activation. Consequently, fusions of antigens with C3d polymers have shown great potential in vaccine design. However, these linear arrays of C3d multimers do not mimic the natural opsonisation of antigens with C3d. Here we investigate the potential of using the unique complement activating characteristics of Staphylococcal immune-evasion protein Sbi to develop a pro-vaccine approach that spontaneously coats antigens with C3 degradation products in a natural way. We show that Sbi rapidly triggers the alternative complement pathway through recruitment of complement regulators, forming tripartite complexes that act as competitive antagonists of factor H, resulting in enhanced complement consumption. These functional results are corroborated by the structure of the complement activating Sbi-III-IV:C3d:FHR-1 complex. Finally, we demonstrate that Sbi, fused with Mycobacterium tuberculosis antigen Ag85b, causes efficient opsonisation with C3 fragments, thereby enhancing the immune response significantly beyond that of Ag85b alone, providing proof of concept for our pro-vaccine approach. |
format | Online Article Text |
id | pubmed-6336717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63367172019-01-25 Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant Yang, Yi Back, Catherine R. Gräwert, Melissa A. Wahid, Ayla A. Denton, Harriet Kildani, Rebecca Paulin, Joshua Wörner, Kristin Kaiser, Wolgang Svergun, Dmitri I. Sartbaeva, Asel Watts, Andrew G. Marchbank, Kevin J. van den Elsen, Jean M. H. Front Immunol Immunology Co-ligation of the B cell antigen receptor with complement receptor 2 on B-cells via a C3d-opsonised antigen complex significantly lowers the threshold required for B cell activation. Consequently, fusions of antigens with C3d polymers have shown great potential in vaccine design. However, these linear arrays of C3d multimers do not mimic the natural opsonisation of antigens with C3d. Here we investigate the potential of using the unique complement activating characteristics of Staphylococcal immune-evasion protein Sbi to develop a pro-vaccine approach that spontaneously coats antigens with C3 degradation products in a natural way. We show that Sbi rapidly triggers the alternative complement pathway through recruitment of complement regulators, forming tripartite complexes that act as competitive antagonists of factor H, resulting in enhanced complement consumption. These functional results are corroborated by the structure of the complement activating Sbi-III-IV:C3d:FHR-1 complex. Finally, we demonstrate that Sbi, fused with Mycobacterium tuberculosis antigen Ag85b, causes efficient opsonisation with C3 fragments, thereby enhancing the immune response significantly beyond that of Ag85b alone, providing proof of concept for our pro-vaccine approach. Frontiers Media S.A. 2019-01-11 /pmc/articles/PMC6336717/ /pubmed/30687332 http://dx.doi.org/10.3389/fimmu.2018.03139 Text en Copyright © 2019 Yang, Back, Gräwert, Wahid, Denton, Kildani, Paulin, Wörner, Kaiser, Svergun, Sartbaeva, Watts, Marchbank and van den Elsen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yang, Yi Back, Catherine R. Gräwert, Melissa A. Wahid, Ayla A. Denton, Harriet Kildani, Rebecca Paulin, Joshua Wörner, Kristin Kaiser, Wolgang Svergun, Dmitri I. Sartbaeva, Asel Watts, Andrew G. Marchbank, Kevin J. van den Elsen, Jean M. H. Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant |
title | Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant |
title_full | Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant |
title_fullStr | Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant |
title_full_unstemmed | Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant |
title_short | Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant |
title_sort | utilization of staphylococcal immune evasion protein sbi as a novel vaccine adjuvant |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336717/ https://www.ncbi.nlm.nih.gov/pubmed/30687332 http://dx.doi.org/10.3389/fimmu.2018.03139 |
work_keys_str_mv | AT yangyi utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT backcatheriner utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT grawertmelissaa utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT wahidaylaa utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT dentonharriet utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT kildanirebecca utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT paulinjoshua utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT wornerkristin utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT kaiserwolgang utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT svergundmitrii utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT sartbaevaasel utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT wattsandrewg utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT marchbankkevinj utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant AT vandenelsenjeanmh utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant |